Biblio

Export 16 results:
Filters: Author is Roy, Marc-André  [Clear All Filters]
2022
Brodeur S, Vanasse A, Courteau J, Courteau M, Stip E, Fleury M-J, Lesage A, Demers M-F, Roy M-A. Antipsychotic utilization trajectories three years after initiating or reinitiating treatment of schizophrenia: A state sequence analysis approach. Acta Psychiatrica ScandinavicaActa Psychiatrica ScandinavicaActa Psychiatr Scand [Internet]. 2022;n/a(n/a). https://doi.org/10.1111/acps.13411
Brodeur S, Courteau J, Vanasse A, Courteau M, Stip E, Fleury M-J, Lesage A, Demers M-F, Corbeil O, Béchard L, Roy M-A. Association between previous and future antipsychotic adherence in patients initiating clozapine: real-world observational study. Br J Psychiatry. 2022;:1-8.
Brodeur S, Vanasse A, Courteau J, Stip E, Lesage A, Fleury M-J, Courteau M, Roy M-A. Comparative effectiveness and safety of antipsychotic drugs in patients with schizophrenia initiating or reinitiating treatment: A Real-World Observational Study. Acta Psychiatr Scand. 2022;.
LeBlanc A, Baron M, Blouin P, Tarabulsy G, Routhier F, Mercier C, Després J-P, Hébert M, De Koninck Y, Cellard C, Collin-Vézina D, Côté N, Dionne É, Fleet R, Gagné M-H, Isabelle M, Lessard L, Menear M, Merette C, Ouellet M-C, Roy M-A, Saint-Jacques M-C, Savard C. For a structured response to the psychosocial consequences of the restrictive measures imposed by the global COVID-19 health pandemic: the MAVIPAN longitudinal prospective cohort study protocol. BMJ Open. 2022;12(4):e048749.
Béchard L, Corbeil O, Thivierge M-A, Assaad I, Boulanger C, Mailhot M-P, Turgeon-Fournier A, Roy M-A, Demers M-F. Management of Rhabdomyolysis in a Patient Treated with Clozapine: A Case Report and Clinical Recommendations. Clin Psychopharmacol Neurosci. 2022;20(1):194-198.
Lesage A, Courteau J, Brodeur S, Stip E, Fleury M-J, Courteau M, Roy M-A, Vanasse A. Urbanicity, Schizophrenia and Equitable Specialist Services Allocation. Can J Psychiatry. 2022;67(2):160-161.
2021
Béchard L, Corbeil O, Plante M, Thivierge M-A, Lafrenière C-É, Roy M-A, Demers M-F. Clozapine rechallenge following neutropenia using granulocyte colony-stimulating factor: A Quebec case series. J Psychopharmacol. 2021;35(9):1152-1157.
2020
Demers M-F, Fortier L, Corbeil O, Breault A-S, Roy M-A. Continuing clozapine despite recurrent neutropenia: A 8 year follow-up case report with granulocyte-colony stimulating factor as-required use. Asian J Psychiatr. 2020;48:101541.
Roy M-A. The Evolution of Long-Acting Antipsychotics Use in Québec between 2003 and 2017. Can J Psychiatry. 2020;:706743720901975.
Corbeil O, Corbeil S, Giroux I, Jacques C, Dorval M, Demers M-F, Roy M-A. Problem Gambling Associated With Aripiprazole in First-Episode Psychosis Patients: A Series of 6 Case Reports. J Clin Psychopharmacol. 2020;40(2):191-194.
2019
Lachance A, Corbeil O, Corbeil S, Chalifour G, Breault A-S, Roy M-A, Demers M-F. Case Reports of Aripiprazole and Problematic Gambling in Schizophrenia: A Critical Review of the Evidence. J Clin Psychopharmacol. 2019;39(4):393-397.
Stip E, Abdel-Baki A, Roy M-A, Bloom D, Grignon S. [Long-acting antipsychotics: The QAAPAPLE algorithm review]. Can J Psychiatry. 2019;:706743719847193.
2018
Roy M-A, Doiron M, Talon-Croteau J, Dupré N, Simard M. Effects of Antiparkinson Medication on Cognition in Parkinson's Disease: A Systematic Review. Can J Neurol Sci. 2018;45(4):375-404.
Roy M-A, Vallières C, Lehoux C, Leclerc L-D, Demers M-F, Achim AM. More intensive probing increases the detection of social anxiety disorders in schizophrenia. Psychiatry Res. 2018;268:358-360.
Roy M-A, Demers M-F, Achim AM. Social anxiety disorder in schizophrenia: a neglected, yet potentially important comorbidity. J Psychiatry Neurosci. 2018;43(4):287-288.
2004
Alméras N, Després J-P, Villeneuve J, Demers M-F, Roy M-A, Cadrin C, Mottard J-P, Bouchard R-H. Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics. J Clin Psychiatry. 2004;65(4):557-64.